 This study found that Sophosbuver-Velpotasper and Sophosbuver-Velpotasper-Voxyloprever were both effective and safe in treating chronic hepatitis C virus, HCV, infection in Korean adults. Both regimens were associated with high-sustained virologic response 12 weeks after completion of treatment, SVR12. Additionally, no deaths or grade 4 laboratory abnormalities were observed during the course of the study. This article was authored by Jong Heo, Yoon Joon Kim, Sung Wook Lee and others.